NCM · Biotechnology

INTS (INTS) Stock

$4.57 +2.70% NCM: INTS Healthcare

Valuation

MetricValue
Price$4.57
Market Cap$12.35M
P/E Ratio-0.60
P/B Ratio0.83
P/S Ratio0.00
EPS (TTM)$-8.56
52-Week High$43.50
52-Week Low$3.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.00%
ROA-85.71%
ROCE-100.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio6.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-8.0M$-8.0M$-17.0M$-12.0M
Net Profit$-8.0M$-8.0M$-11.0M$-16.0M$-12.0M
EPS$-58.00$-55.50$-34.50$-29.25$-8.56
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$2.0M$17.0M$5.0M$14.0M
Total Liabilities$14.0M$17.0M$4.0M$2.0M$2.0M
Cash$5.0M$1.0M$9.0M$3.0M$12.0M
Borrowings$2.0M$4.0M$0$0$0

Latest News

Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight PR Newswire · Jul 15, 2026 Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland MT Newswires · Jul 15, 2026 Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) PR Newswire · Jul 15, 2026 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR Newswire · Jul 1, 2026 Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why Zacks · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-5.0M$-7.0M$-15.0M$-9.0M
Investing Cash Flow$0$0$-6.0M$6.0M$0
Financing Cash Flow$0$0$-2.0M$0$0
Net Cash Flow$-5.0M$-3.0M$7.0M$-6.0M$9.0M
Free Cash Flow$-7.0M$-5.0M$-7.0M$-15.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-105.01%
Quick Ratio4.86
Interest Coverage—
Return 1Y-41.86%
Return 3Y-96.60%
Return 5Y—

Ownership

Insiders Held4.56%
Institutions Held7.01%
Institutions Float Held7.34%
Institutional HolderSharesReport Date
Geode Capital Management, LLC26,0192026-03-31
Sapient Capital LLC26,0062026-06-30
Nano Cap New Millennium Growth Fund L P25,0002026-03-31
Rothschild Wealth, LLC23,2942026-03-31
FNY Investment Advisers, LLC22,0002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
IBIO $1.45 +1.40% -0.91 $22.89M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%
NXTC $5.00 +17.81% -0.26 $18.04M 0.00%

About INTS

INTS is led by CEO Lewis H. Bender, publicly traded since 2023.

INTS stock trades at $4.57 with a market capitalization of $12.35M. The stock is valued at a price-to-earnings (P/E) ratio of -0.60, price-to-book of 0.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.51 and $43.50, and currently trades 89.5% below its 52-week high.

On profitability, INTS generates a return on equity (ROE) of -100.00%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides